Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedereisai.com
Eisai News Release
Get the latest updates from Eisai News Release directly as they happen.
Follow now 64 followers
Latest posts
Last updated 3 months ago
Eisai Rated “A”, the Highest Rating by CDP in the Categories of Climate Change and Water Security
3 months ago
Eisai's news release Eisai Rated “A”, the Highest Rating by CDP in...
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
3 months ago
Eisai's news release Eisai to Provide Guidance on Reducing the Risk of...
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
3 months ago
Eisai's news release Update on Regulatory Review of Lecanemab for Early Alzheimer’s...
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
3 months ago
Eisai's news release FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the...
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-015 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
4 months ago
Eisai's news release Eisai and Merck & Co., Inc., Rahway, NJ, USA...
Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”
4 months ago
Eisai's news release Eisai Releases Corporate Film “1 Percent, 1 Mission. Change...
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE NINTH TIME
4 months ago
Eisai's news release EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION...
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
4 months ago
Eisai's news release FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous...
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer’s Disease
4 months ago
Eisai's news release Elucidation of part of the Mechanism by which Lecanemab...
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
5 months ago
Eisai's news release Fujirebio and Eisai Enter into Memorandum of Understanding for...
“URECE®” (DOTINURAD) APPROVED IN CHINA FOR GOUT PATIENTS WITH HYPERURICEMIA
5 months ago
Eisai's news release “URECE®” (DOTINURAD) APPROVED IN CHINA FOR GOUT PATIENTS WITH...
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Early Alzheimer’s Disease in Mexico
5 months ago
Eisai's news release “LEQEMBI®” (Lecanemab) Approved for the Treatment of Early Alzheimer’s...